128 related articles for article (PubMed ID: 36041229)
1. Myeloma, melphalan, and the taste of transplantation.
Banerjee R
Cancer; 2022 Nov; 128(21):3784-3786. PubMed ID: 36041229
[No Abstract] [Full Text] [Related]
2. A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation.
Scordo M; Shah GL; Adintori PA; Knezevic A; Devlin SM; Buchan ML; Preston EV; Lin AP; Rodriguez NT; Carino CA; Nguyen LK; Sitner NC; Barasch A; Klang MG; Maloy MA; Mastrogiacomo B; Carlow DC; Schofield RC; Slingerland AE; Slingerland JB; Stein-Thoeringer CK; Lahoud OB; Landau HJ; Chung DJ; van den Brink MRM; Peled JU; Giralt SA
Cancer; 2022 Nov; 128(21):3850-3859. PubMed ID: 36041227
[TBL] [Abstract][Full Text] [Related]
3. High-dose melphalan in 1 day versus over 2 days followed by autologous stem cell transplantation as consolidation treatment in patients with multiple myeloma.
Aydin M; Tang MW; Wondergem MJ; de Leeuw DC; Wegman JJ; Biemond BJ; van de Donk NWCJ; Zweegman S; Meijer E; Nur E
Br J Haematol; 2022 Mar; 196(6):e67-e70. PubMed ID: 34961917
[No Abstract] [Full Text] [Related]
4. Still learning the right way to administer melphalan in autologous transplantation.
Lad DP; Patil AN; Malhotra P
Bone Marrow Transplant; 2020 Dec; 55(12):2357-2358. PubMed ID: 32523051
[No Abstract] [Full Text] [Related]
5. Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.
Monahan K; Kleman A; Thapa B; Szabo A; D'Souza A; Dhakal B; Jerkins JH; Pasquini MC; Hamadani M; Hari PN; Chhabra S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2229-2236. PubMed ID: 32920204
[TBL] [Abstract][Full Text] [Related]
6. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
[TBL] [Abstract][Full Text] [Related]
7. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.
Song GY; Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS
Leuk Lymphoma; 2020 Nov; 61(11):2714-2721. PubMed ID: 32580672
[TBL] [Abstract][Full Text] [Related]
8. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
[TBL] [Abstract][Full Text] [Related]
9. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma.
Srour SA; Milton DR; Bashir Q; Nieto Y; Saini N; Daher M; Ramdial J; Im J; Hosing C; Delgado R; Manasanch E; Lee HC; Thomas S; Kaufman G; Patel K; Popat U; Weber D; Orlowski R; Shpall E; Champlin RE; Qazilbash MH
Haematologica; 2021 Dec; 106(12):3211-3214. PubMed ID: 34407606
[No Abstract] [Full Text] [Related]
10. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
11. Melphalan-based autologous transplant in octogenarian multiple myeloma patients.
Saini NY; Patel R; Varma A; Bashir Q; Delgado R; Rondon G; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Weber DM; Thomas SK; Lee HC; Manasanch EE; Patel KK; Orlowski RZ; Champlin RE; Qazilbash MH
Am J Hematol; 2019 Jan; 94(1):E2-E5. PubMed ID: 30300461
[No Abstract] [Full Text] [Related]
12. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of autologous hematopoietic stem cell transplantation pretreated with Melphalan hydrochloride for injection in the treatment of 125 cases of multiple myeloma].
Huang WY; Liu W; Liu HM; Xu Y; Wang Q; Du CX; Xiong WJ; Sui WW; Tian F; Wang J; Yi SH; An G; Qiu LG; Zou DH
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):148-150. PubMed ID: 36948870
[No Abstract] [Full Text] [Related]
14. Microbiota dysbiosis after high-dose melphalan and autologous hematopoietic cell transplantation in multiple myeloma.
Malard F; Battipaglia G; Gaugler B; Siblany L; van de Wyngaert Z; Bonnin A; Duléry R; Banet A; Stocker N; Ricard L; Brissot E; Mohty M
Bone Marrow Transplant; 2023 Nov; 58(11):1275-1278. PubMed ID: 37608072
[No Abstract] [Full Text] [Related]
15. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
16. IgD Myeloma: Dialysis-Independence following High-Dose Melphalan and Autologous Stem Cell Transplantation.
McGlynn F; Glavey S; Sargent J; Thornton P; Conlon P; Murphy P; Quinn J
Acta Haematol; 2018; 140(3):176-177. PubMed ID: 30300899
[No Abstract] [Full Text] [Related]
17. Autologous hematopoietic stem-cell transplantation for multiple myeloma.
Harousseau JL; Moreau P
N Engl J Med; 2009 Jun; 360(25):2645-54. PubMed ID: 19535803
[No Abstract] [Full Text] [Related]
18. High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma.
Ali MO; Al Hadidi S
Transplant Cell Ther; 2022 Sep; 28(9):572-580. PubMed ID: 35750284
[TBL] [Abstract][Full Text] [Related]
19. Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.
Costa LJ; Landau HJ; Chhabra S; Hari P; Innis-Shelton R; Godby KN; Hamadani M; Tamari R; Anderton K; Dixon P; Giralt SA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1379-1385. PubMed ID: 29410301
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine, busulfan, and melphalan conditioning for autologous stem-cell transplants in multiple myeloma.
Gahrton G
Lancet Haematol; 2017 Jun; 4(6):e250-e251. PubMed ID: 28522109
[No Abstract] [Full Text] [Related]
[Next] [New Search]